Show simple item record

dc.contributor.authorGagel, R. F.
dc.contributor.authorCostanza, Mary E.
dc.contributor.authorDeLellis, R. A.
dc.contributor.authorNorton, R. A.
dc.contributor.authorBloom, S. R.
dc.contributor.authorMiller, H. H.
dc.contributor.authorUcci, A.
dc.contributor.authorNathanson, L.
dc.date2022-08-11T08:11:05.000
dc.date.accessioned2022-08-23T17:32:59Z
dc.date.available2022-08-23T17:32:59Z
dc.date.issued1976-12-01
dc.date.submitted2007-07-30
dc.identifier.citation<p>Arch Intern Med. 1976 Dec;136(12):1429-35.</p>
dc.identifier.issn0003-9926 (Print)
dc.identifier.doi10.1001/archinte.1976.03630120075019
dc.identifier.pmid187136
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51069
dc.description.abstractA patient with watery diarrhea, hypokalemia, hypochlorhydria, and a non-beta islet cell carcinoma of the pancreas (Verner-Morrison syndrome) was found to have an elevated vasoactive intestinal peptide (VIP) concentration in the plasma as well as in the tumor. Treatment with streptozocin resulted in a dramatic subjective and objective tumor response in this patient. Plasma VIP concentration fell into the normal range after four courses of treatment, diarrhea ceased after the third course of therapy, and measurable tumor mass markedly decreased during that same period of time. The patient remains in clinical remission with no evidence of tumor regrowth 18 months after the beginning of treatment. In this patient, plasma VIP measurements were an excellent marker of tumor activity and correlated well with objective disease measurements and clinical response.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=187136&dopt=Abstract">Link to article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1001/archinte.1976.03630120075019
dc.subjectAdenoma, Islet Cell
dc.subjectDiarrhea
dc.subjectFemale
dc.subjectHumans
dc.subjectHypokalemia
dc.subjectMiddle Aged
dc.subjectPancreatic Neoplasms
dc.subjectStomach Diseases
dc.subjectStreptozocin
dc.subjectSyndrome
dc.subjectVasoactive Intestinal Peptide
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.subjectWomen's Studies
dc.titleStreptozocin-treated Verner-Morrison Syndrome: plasma vasoactive intestinal peptide and tumor responses
dc.typeJournal Article
dc.source.journaltitleArchives of internal medicine
dc.source.volume136
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/wfc_pp/82
dc.identifier.contextkey330318
html.description.abstract<p>A patient with watery diarrhea, hypokalemia, hypochlorhydria, and a non-beta islet cell carcinoma of the pancreas (Verner-Morrison syndrome) was found to have an elevated vasoactive intestinal peptide (VIP) concentration in the plasma as well as in the tumor. Treatment with streptozocin resulted in a dramatic subjective and objective tumor response in this patient. Plasma VIP concentration fell into the normal range after four courses of treatment, diarrhea ceased after the third course of therapy, and measurable tumor mass markedly decreased during that same period of time. The patient remains in clinical remission with no evidence of tumor regrowth 18 months after the beginning of treatment. In this patient, plasma VIP measurements were an excellent marker of tumor activity and correlated well with objective disease measurements and clinical response.</p>
dc.identifier.submissionpathwfc_pp/82
dc.contributor.departmentDepartment of Medicine, Division of Hematology/Oncology
dc.source.pages1429-35


This item appears in the following Collection(s)

Show simple item record